Novavax (NVAX): Un Nuevo Comienzo

Está claro que tu sistema es más sutil que el mío jjjjj, pero ambos buscan lo mismo.😉

Buen post!

Pues asi esta la foto antes de la fiesta

Lo sacan antes o despues de la apertura del mercado?

Al cierre

MODO VACACIONES:

Estoy de vacaciones y voy controlando el valor a traves de ST, a ver que pasa hoy, os deseo surte a todos (los largos claro :)

Si hay pump and dump, me voy hechndo leches...

pero no me dijiste que hasta la luna y mas alla ...o a por la ruina total?????

ya se te han quitado las ganas o que?

articulito bloguero

ni lo he leido

https://seekingalpha.com/article/4096407-novavax-reaching-critical-mass?auth_param=456d7:1cok1u3:581f226d809728057ad4af7c07749f8b&uprof=44

jeje, mas vale pájaro en mano que 100 volando.

esperar una fase 2b + fase 3 , demasiado tiempo. mas vale ir tradeando en barras de menos tiempo.

Novavax EPS in-line, beats on revenue

Aug. 8, 2017 4:09 PM ET|By:  Gaurav Batavia, SA News Editor 

Novavax (NASDAQ: NVAX): Q2 EPS of -$0.16 in-line.

Revenue of $6.73M (+169.2% Y/Y) beats by $0.43M.

http://ir.novavax.com/news-releases/news-release-details/novavax-reports-second-quarter-2017-financial-results

A destacar

Novavax’ nanoparticle flu vaccine demonstrates superior immunogenicity and protection compared to market leader in preclinical challenge studies. In head-to-head comparison studies against Fluzone^® High-Dose, Novavax’ nanoparticle influenza vaccine with our proprietary Matrix-M™ adjuvant (NanoFlu) demonstrated significantly stronger and broader immune responses against matched and unmatched influenza strains, including a series of “drifted” strains evolved over more than a decade of influenza seasons. NanoFlu was also protective in an established challenge model against both a matched and a ten-year old unmatched strain. Further details will be published in the near future in a peer-reviewed journal and presented at scientific conferences.

• Initiation of a Phase 1/2 clinical trial of the Company’s NanoFlu vaccine candidate in a head-to-head comparison to Fluzone High-Dose. Data from this trial should be available in the fourth quarter of 2017.

y $187.3 million in cash, mejor de lo que esperaba ...

Sobre la dilucion ATM

During the six months ended June 30, 2017, the Company sold 18.0 million shares of common stock between February 28, 2017 and June 27, 2017 (the “Trading Period”) resulting in $22.7 million in net proceeds (this amount excludes $0.3 million received in the third quarter of 2017 for shares traded in late June 2017). The weighted average sales price achieved during the Trading Period was $1.31 per share. F rom July 1, 2017 through August 4, 2017, the Company sold an additional 3.9 million shares of common stock resulting in $5.7 million in net proceeds. Through August 4, 2017, the Company sold aggregate gross proceeds of $29.4 million of common stock of the $75 million total amount available under the Sales Agreement.

Alrededor del 40% de la dilucion ATM ya ha sido ejecutada

no hay pesca en after, plana,  a ver ahora que deciden hacer día a día con ella.

En la conference dicen que la proxima semana conversaciones con BARDA por fondos 😍😍😍

Gracias framus por la información!!!!

A ver si me leo mañana la transcripcion y me empapo de mas detalle

Un lujo tenerte en el foro, Framus !!.

Y que no te paguen por tanto curro¡.. Vas a tener que darnos tu dirección para que te enviemos una caja de cervezas.